NightHawk Biosciences Inc (NHWK)

[dia76ca]

IR says the SITC poster will be put up on the company website... meanwhile here are the conclusions from the preclinical studies.

-ComPACT amplifies antigen-specific CD4+ and CD8+ T cells at both priming and
boosting, generating more MPEC than OX40 agonist antibodies.
-ComPACT plus TL1a.Ig induces expansion of antigen specific Treg (that are functional
and highly suppressive) and augments antigen-specific CD8+ T cell expansion.
-ComPACT demonstrates antigen specificity, without the off-target systemic
inflammatory signature seen with OX40 agonist mAbs.
-ComPACT synergizes with checkpoint inhibition (aPD1 and aPDL1) to maximize
antigen-specific T cell proliferation, memory cell response, and tumor eradication.
-ComPACT delivers immunotherapy and co-stimulatory fusion protein in a single
compound, and synergizes strongly with checkpoint inhibitors. Future combinations of
the co-stimulators and checkpoint inhibitors may significantly improve patient outcomes.